Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
Abstract Introduction We aimed to characterize the clinical impact of amyloid PET (APET) in a veteran population with cognitive decline by comparing differences in management between those who did and did not have an APET. Methods This was a retrospective observational study. Poisson regressions and...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12320 |
| _version_ | 1797948963239755776 |
|---|---|
| author | Ana Laura Vives‐Rodriguez Kylie A. Schiloski Anna Marin Ryan Wang Gabor P. Hajos Rachel Powsner Renée DeCaro Andrew E. Budson Katherine W. Turk |
| author_facet | Ana Laura Vives‐Rodriguez Kylie A. Schiloski Anna Marin Ryan Wang Gabor P. Hajos Rachel Powsner Renée DeCaro Andrew E. Budson Katherine W. Turk |
| author_sort | Ana Laura Vives‐Rodriguez |
| collection | DOAJ |
| description | Abstract Introduction We aimed to characterize the clinical impact of amyloid PET (APET) in a veteran population with cognitive decline by comparing differences in management between those who did and did not have an APET. Methods This was a retrospective observational study. Poisson regressions and logistic regression were used for comparisons. Results Out of 565 veterans, 197 underwent APET; positivity rate was 36.55%. Having an APET was associated with longer follow‐up, and increased diagnostic variability; it was not associated with number of additional studies, cholinesterase inhibitors prescription, or referrals to research. A positive APET was associated with less diagnostic variability, fewer additional tests, greater cholinesterase inhibitor prescriptions, and more research referrals. Discussion In a medically complex, real‐world population, APET yielded lower positivity rates and was not associated with classical clinical utility variables when comparing patients with and without an APET. APET may be used more to “rule out” rather than to confirm Alzheimer's disease. Highlights Amyloid PET was associated with longer follow‐up, and higher diagnostic variability. No association was seen with cholinesterase inhibitors prescription, or referrals to research. In complex patients, expected amyloid PET positivity rates are lower than previously described. Amyloid PETs were used to “rule out” AD than to confirm the diagnosis of AD. |
| first_indexed | 2024-04-10T21:52:53Z |
| format | Article |
| id | doaj.art-0370a684e233442abda73393b6621073 |
| institution | Directory Open Access Journal |
| issn | 2352-8737 |
| language | English |
| last_indexed | 2024-04-10T21:52:53Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj.art-0370a684e233442abda73393b66210732023-01-18T11:41:04ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12320Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinicAna Laura Vives‐Rodriguez0Kylie A. Schiloski1Anna Marin2Ryan Wang3Gabor P. Hajos4Rachel Powsner5Renée DeCaro6Andrew E. Budson7Katherine W. Turk8Center for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USADepartment of Neurology Boston University School of Medicine Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USADepartment of Radiology VA Boston Healthcare System Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USACenter for Translational Cognitive Neuroscience VA Boston Healthcare System Boston Massachusetts USAAbstract Introduction We aimed to characterize the clinical impact of amyloid PET (APET) in a veteran population with cognitive decline by comparing differences in management between those who did and did not have an APET. Methods This was a retrospective observational study. Poisson regressions and logistic regression were used for comparisons. Results Out of 565 veterans, 197 underwent APET; positivity rate was 36.55%. Having an APET was associated with longer follow‐up, and increased diagnostic variability; it was not associated with number of additional studies, cholinesterase inhibitors prescription, or referrals to research. A positive APET was associated with less diagnostic variability, fewer additional tests, greater cholinesterase inhibitor prescriptions, and more research referrals. Discussion In a medically complex, real‐world population, APET yielded lower positivity rates and was not associated with classical clinical utility variables when comparing patients with and without an APET. APET may be used more to “rule out” rather than to confirm Alzheimer's disease. Highlights Amyloid PET was associated with longer follow‐up, and higher diagnostic variability. No association was seen with cholinesterase inhibitors prescription, or referrals to research. In complex patients, expected amyloid PET positivity rates are lower than previously described. Amyloid PETs were used to “rule out” AD than to confirm the diagnosis of AD.https://doi.org/10.1002/trc2.12320amyloid PETAlzheimer's diseasecognitive declineclinical impact |
| spellingShingle | Ana Laura Vives‐Rodriguez Kylie A. Schiloski Anna Marin Ryan Wang Gabor P. Hajos Rachel Powsner Renée DeCaro Andrew E. Budson Katherine W. Turk Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic Alzheimer’s & Dementia: Translational Research & Clinical Interventions amyloid PET Alzheimer's disease cognitive decline clinical impact |
| title | Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic |
| title_full | Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic |
| title_fullStr | Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic |
| title_full_unstemmed | Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic |
| title_short | Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic |
| title_sort | impact of amyloid pet in the clinical care of veterans in a tertiary memory disorders clinic |
| topic | amyloid PET Alzheimer's disease cognitive decline clinical impact |
| url | https://doi.org/10.1002/trc2.12320 |
| work_keys_str_mv | AT analauravivesrodriguez impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT kylieaschiloski impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT annamarin impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT ryanwang impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT gaborphajos impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT rachelpowsner impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT reneedecaro impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT andrewebudson impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic AT katherinewturk impactofamyloidpetintheclinicalcareofveteransinatertiarymemorydisordersclinic |